Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q3 2018 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Pardes Biosciences Inc | 4 | Q3 2022 | 57.4% |
Theseus Pharmaceuticals, Inc. | 4 | Q3 2022 | 16.7% |
Gemini Therapeutics, Inc. | 4 | Q3 2022 | 12.0% |
Quantum-Si Incorporated | 4 | Q3 2022 | 10.5% |
Kinnate Biopharma Inc. | 4 | Q3 2022 | 10.5% |
Compass Therapeutics, Inc. | 4 | Q3 2022 | 10.6% |
Adicet Bio, Inc. | 4 | Q3 2022 | 7.3% |
Enanta Pharmaceuticals, Inc. | 3 | Q3 2022 | 3.5% |
Cue Health Inc. | 2 | Q1 2022 | 13.7% |
Cullinan Oncology, Inc. | 2 | Q1 2022 | 4.8% |
View Foresite Capital Opportunity Management V, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
4 | 2024-07-03 |
3 | 2024-06-27 |
4 | 2024-04-05 |
4 | 2023-08-31 |
4 | 2023-07-19 |
4 | 2023-05-10 |
4 | 2023-04-06 |
4 | 2023-02-22 |
4 | 2023-01-03 |
13F-HR | 2022-11-14 |
View Foresite Capital Opportunity Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.